6G
6GJ.F Glaukos Corporation
- Market cap
- EUR 12.4B
- P/E
- -
- P/B
- 19.45x
- ROE
- -6.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 6GJ.F undervalued?
Graham numberThe Graham number of Glaukos Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Glaukos Corporation fundamental analysis
No fundamental analysis for Glaukos Corporation yet.
Glaukos Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Glaukos Corporation
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the…
Full company profileGlaukos Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Glaukos Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 114M | 159M | 181M | 237M | 225M | 294M | 283M | 315M | 383M | 507M | 730M |
| Gross Profit | 98.2M | 138M | 156M | 198M | 133M | 227M | 214M | 239M | 289M | 283M | 598M |
| Operating Income | 4.24M | -2.28M | -13.0M | -50.3M | -124M | -52.9M | -102M | -124M | -108M | -200M | -46.4M |
| EBITDA | - | 5.53M | -6.74M | -37.6M | -83.6M | -35.9M | -84.7M | -82.1M | -95.6M | -146M | 2.70M |
| Net Income | 4.52M | -92.0K | -13.0M | 15.4M | -120M | -49.6M | -99.2M | -135M | -146M | -188M | -48.2M |
| EPS | - | 0.00 | -0.36 | 0.35 | -2.66 | -1.06 | -2.08 | -2.74 | -2.59 | -3.26 | -0.81 |
| Balance Sheet | |||||||||||
| Total Assets | 134M | 166M | 207M | 818M | 1.01B | 1.05B | 1.00B | 940M | 975M | 893M | 980M |
| Total Liabilities | 17.1M | 27.6M | 33.1M | 145M | 338M | 463M | 472M | 479M | 208M | 237M | 262M |
| Shareholders' Equity | 117M | 138M | 174M | 673M | 667M | 587M | 530M | 462M | 767M | 656M | 717M |
| Cash & Short-term Investments | 6.49M | 24.5M | 29.8M | 62.4M | 96.6M | 101M | 120M | 93.5M | 170M | 90.8M | 162M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 12.3M | 26.1M | 18.9M | -369K | -23.0M | 24.7M | -33.1M | -51.2M | -61.3M | -14.8M | 54.5M |
| Capital Expenditure | 6.28M | 6.31M | 10.3M | 4.72M | 6.94M | 47.8M | 30.3M | 24.3M | 6.30M | 24.3M | 11.7M |
| Free Cash Flow | - | 19.2M | 8.55M | -5.09M | -29.9M | -23.1M | -63.3M | -75.5M | -67.6M | -39.1M | 42.8M |
| Ratios | |||||||||||
| ROE | 3.9% | -0.1% | -7.4% | 2.3% | -18.0% | -8.4% | -18.7% | -29.2% | -19.1% | -28.6% | -6.7% |
| ROA | 3.4% | -0.1% | -6.3% | 1.9% | -12.0% | -4.7% | -9.9% | -14.3% | -15.0% | -21.0% | -4.9% |
| Net Profit Margin | 4.0% | -0.1% | -7.1% | 6.5% | -53.5% | -16.9% | -35.1% | -42.8% | -38.2% | -37.0% | -6.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Glaukos Corporation dividends
Glaukos Corporation has not paid dividends in the last 9 fiscal years.
Who owns Glaukos Corporation
- Insiders 3.60%
- Institutions 96.41%
- Public & others 0.00%
- Shares outstanding 59.2M
- Free float 57.0M
Glaukos Corporation company profile
- Company name
- Glaukos Corporation
- Ticker
- 6GJ.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,094
- Fiscal year end
- December
- Address
- One Glaukos Way, Aliso Viejo, CA, United States, 92656
- Phone
- 949 367 9600
- Website
- glaukos.com
About Glaukos Corporation
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Glaukos Corporation management
9- Mr. Thomas William BurnsChairman & CEO · born 1961
- Mr. Joseph E. GilliamPresident & COO · born 1976
- Mr. Alex R. ThurmanSenior VP & CFO · born 1970
- Dr. Tomas Navratil Ph.D.Chief Development Officer · born 1977
- Mr. Christopher William LewisVice President of Investor Relations & Corporate Affairs
- Mr. Robert L. Davis J.D.Senior VP, General Counsel & Business Development · born 1966
- Ms. Diana A. SchererVP of Compliance & Deputy General Counsel
- Ms. Michele M. AllegrettoSenior Vice President of Human Resources
- Mr. L. Jay Katz FACS, M.D.Chief Medical Officer